METiS TechBio a world leader in AI-driven nano-delivery innovation announced the official launch of NanoForge, the world’s first end-to-end AI-driven nano-delivery platform.
NanoForge is the first fully integrated AI platform for nano-delivery discovery and design. By leveraging quantum chemistry and molecular dynamics simulations, it combines METiS’ proprietary high-throughput wet-lab screening platform with in-house developed generative lipid language models, AI agents, and the world’s largest LNP library comprising over 10 million lipid structures.
The platform supports a closed-loop workflow encompassing molecular generation, property prediction, optimisation, and final candidate selection. Via continuous learning, NanoForge steadily enhances its data infrastructure and predictive capabilities.
So far, the company has achieved breakthrough targeted LNP delivery to eight organs and tissues in vivo, including the liver, lung, heart, muscle, tumours, and CNS. To date, METiS has over ten pipeline programs including seven preclinical candidates and four clinical-stage programs with the most advanced nearing pre-NDA stage.
Dr. Chris Lai, Co-Founder and Chief Executive Officer of METiS, said: “NanoForge embodies a new paradigm—from biotech to techbio—that we have built over the past five years. In the specialised field of nano-delivery, we have proven that combining large-scale AI innovation with closed-loop experimental iteration drives remarkable gains in efficiency and technical capability. Rooted in independent R&D and world-class science, METiS is poised to become a new engine for innovative drug development.”
Recently, nano-delivery systems have shifted from being a development bottleneck into a key enabling technology. The first mRNA COVID-19 vaccine approved in 2020 demonstrated precise delivery and safety, enabling efficient antigen expression and reshaping the landscape of vaccine development.
